Study of people using Skytrofa in the United States
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism clinical trials.
This study looks at how well and how safely Skytrofa (lonapegsomatropin) works for real-world patients in the U.S. It mainly gathers information from routine care to help doctors understand expected benefits and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking Skytrofa (lonapegsomatropin)
- Your care is currently being managed in the United States
- You (or your guardian, if applicable) can sign an informed consent form
- You are not taking part in any other clinical study that changes your treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the safety of lonapegsomatropin in children being treated for growth hormone deficiency (GHD). It’s meant to check for side effects and make sure the medicine continues to be safe in real-world use.
This study looks at how different types of growth hormone treatment affect your body’s metabolism and growth. It will compare standard daily growth hormone with a longer-acting version, and track your health over time to see which works better.
This study follows children who are short for their age and checks how safe and effective growth hormone is over the long term. It may help families understand expected benefits and side effects for their specific growth-related condition.
This study follows adults with growth hormone deficiency who start (or have started) Sogroya to learn about its long-term safety. It does not change your treatment—it mainly checks for side effects and health outcomes over time.
This study tests whether an investigational drug can help children with idiopathic short stature (short height with no known cause) grow taller. It may be an option for children who are very short for their age and have not responded well to standard growth hormone therapy.
This study looks at how well somatrogon works for children 3 years and older with growth hormone deficiency. It may help you understand if this treatment is an option for your child.
Hear when a new Growth Hormone Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.